Godavari Biorefineries Ltd on Monday said it has received a patent from the Japan Patent Office for its invention titled “Use of Compounds for Treating Viral Infections”.
According to the official press release, the patent covers the second medical use of the company’s lead compound MSP22 and its derivatives for antiviral applications through inhibition of Vacuolar ATPase (V- ATPase).
The company said the compounds inhibit V-ATPase activity in cells, a mechanism involved in viral infection pathways. The patent names Maithili Athavale, Sandip Gavade, Prashant Kharkar and Sangeeta Srivastava as inventors
Focus on life sciences research
The development is part of the company’s life sciences programme led by Sathgen Therapeutics, its biotechnology arm focused on drug discovery.
Godavari Biorefineries said the compounds target host-cell pathways linked to viral infections and may affect viral entry and replication. The patent in Japan adds to its intellectual property portfolio for antiviral research.
Samir Somaiya, Chairman and Managing Director, Godavari Biorefineries Ltd, said, “Securing this patent in Japan reflects a natural extension of our ongoing work in drug discovery. As we progressed with our R&D efforts on lead molecules, we identified their potential to inhibit mechanisms such as V-ATPase, which are relevant in antiviral applications".
Sangeeta Srivastava, Executive Director, said, “Research that targets the V-ATPase, which is a cellular enzyme complex exploited by viruses, could open new directions in antiviral therapy"
The company said the research could support the development of therapies targeting multiple viral families by focusing on host-cell mechanisms rather than specific viruses.
Source: Economictimes.com
